Skip to main content

Table 6 The pooled prevalence susceptibility of tedizolid, oritavancin, dalbavancin, and telavancin against MRSA isolates

From: Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis

Antibiotics

Number of studies

Number of MRSA Isolates

Proportion (95% CI)

chi2

Heterogeneity P

I2

p

Dalbavancin

11

28539

1.00, (1.00,1.00)

8.22

0.61

0.00%

0.00

Oritavancin

2

420

1.00, (1.00,1.00)

   

0.00

Tedizolid

21

12204

1.00, (1.00,1.00)

7.57

0.99

0.00%

0.00

Telavancin

8

7353

1.00, (1.00,1.00)

3.26

0.86

0.00%

0.00